MRI and Blood Biomarkers for the Prediction of Neurocognitive Decline Following Brain Radiation (NCT05087888) | Clinical Trial Compass
TerminatedNot Applicable
MRI and Blood Biomarkers for the Prediction of Neurocognitive Decline Following Brain Radiation
Stopped: \<75% participation
United States9 participantsStarted 2019-08-22
Plain-language summary
This study determines whether non-invasive evaluation using repeated magnetic resonance imaging (MRI) scans and repeated blood biomarker measurements can be used to predict changes in a person's mental functions that result from radiation exposure to the brain. This study may let researchers monitor patient responses to treatment and the disease better and possibly make changes to patient treatment, if needed.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients must be age \>= 18 years
* Patients must be planned for fractionated radiotherapy that will be delivered over at least 5 weeks and that will expose the brain to radiation
* Patients must have Karnofsky performance status (KPS) \>= 80
* Patients must be able to obtain an MRI scan with gadolinium contrast
* Female patients of childbearing age must not be pregnant as determined with a serum beta human chorionic gonadotropin (HCG) no greater than 14 days prior to study registration, or breast-feeding. (The exclusion is made because gadolinium may be teratogenic in pregnancy). Pregnancy tests are part of standard of care routine if a patient is receiving radiation treatment
* Patient must be fluent enough in English to complete neurocognitive testing
* Education of \>= 12 years (high school graduate or equivalent) by patient self-report
* Patient is able to complete an in-person and electronic neurocognitive assessments (i.e. is alert and has the ability to comprehend and complete the assessments)
* Patient has no history of psychiatric or medical conditions that would result in an inability to complete serial neurocognitive tests, severe claustrophobia, prior cerebrovascular event(s), degenerative neurological diagnoses (e.g., dementia, Parkinson's, multiple sclerosis \[MS\]) or severe psychiatric illness (e.g., schizophrenia) that may impact neurocognitive and imaging assessments
Exclusion Criteria:
* Previous brain radiation without comprehensi…
What they're measuring
1
To describe changes of image features on conventional T1- and T2- weighted imaging, and quantitative changes on the multipara metric MRI.